Showing 4931-4940 of 7167 results for "".
- ASDS News: CellFX Clears Low-Risk Basal Cell Carcinoma Lesionshttps://practicaldermatology.com/news/asds-news-cellfx-clears-low-risk-basal-cell-carcinoma-lesions/2461374/CellFX procedure is effective for low-risk superficial and nodular basal cell carcinoma lesion clearance, according to research presented at the 2022 American Society for Dermatologic Surgery (ASDS) Annual Meeting. "It is exciting and encouraging to see complete clearance of b
- Candesant Biomedical Introduces New SweatTech Initiative at ASDShttps://practicaldermatology.com/news/candesant-biomedical-novel-investigational-technology-for-hyperhydrosis/2461371/Candesant Biomedical is introducing a new initiative – SweatTech™ – at the ASDS annual meeting. The company is also developing a new novel technology (currently under FDA review) that reduces axillary hyperhidrosis. Their “TAT” (targeted alkali thermolysis) pat
- Business News: Incyte Buys Startup Villarishttps://practicaldermatology.com/news/business-news-incyte-buys-startup-villaris/2461370/Incyte will pay $70 million upfront to buy Villaris Therapeutics, a startup working on an experimental drug for vitiligo. Villaris’ lead asset, auremolimab (VM6), an anti-IL-15Rβ monoclonal antibody (mAb), is expected to enter clinical development in 2023. Villaris&
- DermTech Presents on Value of Decentralization of Clinical Trialshttps://practicaldermatology.com/news/dermtech-presents-on-value-of-decentralization-of-clinical-trials/2461368/Technology can help decentralize clinical trials, leading to greater patient satisfaction, a more diverse patient population, better retention and cost savings, according to a presentation by DermTech at Outsourcing in Clinical Trials Southern California, held from Sept. 28-29 in San Di
- Johnson & Johnson Announces Kenvue as the Name for New Consumer Health Companyhttps://practicaldermatology.com/news/johnson-johnson-announces-kenvue-as-the-name-for-new-consumer-health-company/2461363/Johnson & Johnson’s planned new consumer health company will be named...Kenvue. Kenvue (pronounced ken·view), is inspired by two powerful ideas: “ken” – meaning knowledge, an English word primarily used in Scotland, and “vue,” ref
- Evommune Initiates Phase 2a Proof-of-Concept Clinical Trial of EVO101 in ADhttps://practicaldermatology.com/news/evommune-initiates-phase-2a-proof-of-concept-clinical-trial-of-evo101-in-ad/2461362/Evommune, Inc. enrolled the first patient in a Phase 2a proof-of-concept clinical trial evaluating EVO101, a novel small molecule inhibitor of interleukin 1 receptor-associated kinase 4 (IRAK4), in patients with atopic dermatitis (AD). The Phase 2a trial is a randomized, double-bl
- L'Oréal Breaks Ground on New Research and Innovation Center in NJhttps://practicaldermatology.com/news/loreal-breaks-ground-on-new-research-and-innovation-center-in-nj/2461361/L'Oréal USA is opening a new, state-of-the-art Research & Innovation (R&I) Center in Clark, New Jersey, replacing its existing facilities that it has occupied in the area for more than six decades. The $140 million development project represents the most significant investment
- Positive Topline Results from Pivotal Phase 3 Trial of Arcutis Biotherapeutics' Roflumilast Foam in Scalp and Body Psoriasishttps://practicaldermatology.com/news/positive-topline-results-from-pivotal-phase-3-trial-of-arctuis-biotherapeutics-roflumilast-foam-in-scalp-and-body-psoriasis/2461359/Topline results from the ARRECTOR Pivotal Phase 3 trial evaluating Arcutis Biotherapeutics, Inc.'s roflumilast foam 0.3% were positive for the treatment of adults and adolescents with scalp and body psoriasis. The study met its co-primary endpoints of S-
- FDA Clears CellFX System for the Treatment of SHhttps://practicaldermatology.com/news/fda-clears-cellfx-system-for-the-treatment-of-sh/2461358/The U.S. Food and Drug Administration (FDA) granted Pulse Bioscience’s CellFX System (FDA) 510(k)marketing clearance for the treatment of sebaceous hyperplasia in patients with Fitzpatrick skin types I-II. This specific indication clearance enhances the CellFX
- Spotlight On: Honey and Its Role in Wound Healinghttps://practicaldermatology.com/news/spotlight-on-honey/2461353/Honey may play a role in wound healing due to its antimicrobial and tissue-regenerative properties, according to scientists from the University of Manchester. Their review of more than 250 articles spans 85 years -with oldest article from 1937- is published in the journal Pharmaceu